EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?

Lana Ganoci iD, Jozefina Palić iD, Vladimir Trkulja iD, Katarina Starčević iD, Livija Šimičević iD, Nada Božina, Martina Lovrić-Benčić, Zdravka Poljaković, Tamara Božina iD

Genes · 2024

DOI: 10.3390/genes15050607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Lana Ganoci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Cr…. Hauptthemen laut MEDLINE: Clopidogrel, Haplotypes, Cytochrome P-450 CYP2C19, Hemorrhage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A recently discovered haplotype—CYP2C:TG—determines the ultrarapid metabolism of several CYP2C19 substrates. The platelet inhibitor clopidogrel requires CYP2C19-mediated activation: the risk of ischemic events is increased in patients with a poor (PM) or intermediate (IM) CYP2C19 metabolizer phenotype (vs. normal, NM; rapid, RM; or ultrarapid, UM). We investigated whether the CYP2C:TG haplotype affected efficacy/bleeding risk in clopidogrel-treated patients. Adults (n = 283) treated with clopidogrel over 3–6 months were classified by CYP2C19 phenotype based on the CYP2C19*2*17 genotype, and based on the CYP2C19/CYP2C cluster genotype, and regarding carriage of the CYP2:TG haplotype, and were balanced on a number of covariates across the levels of phenotypes/haplotype carriage. Overall, 45 (15.9%) patients experienced ischemic events, and 49 (17.3%) experienced bleedings. By either classification, the incidence of ischemic events was similarly numerically higher in PM/IM patients (21.6%, 21.8%, respectively) than in mutually similar NM, RM, and UM patients (13.2–14.8%), whereas the incidence of bleeding events was numerically lower (13.1% vs. 16.6–20.5%). The incidence of ischemic events was similar in CYP2C:TG carries and non-carries (14.1% vs. 16.1%), whereas the incidence of bleedings appeared mildly lower in the former (14.9% vs. 20.1%). We observed no signal to suggest a major effect of the CYP2C19/CYP2C cluster genotype or CYP2C:TG haplotype on the clinical efficacy/safety of clopidogrel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelHaplotypesCytochrome P-450 CYP2C19HemorrhagePlatelet Aggregation InhibitorsHumansMaleFemaleAgedMiddle AgedGenotypeTiclopidine

Stichwörter der Autor:innen

CYP2C19 phenotypeCYP2C:TG haplotypebleedingclopidogrelefficacy

Substanzen

ClopidogrelCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsCYP2C19 protein, humanTiclopidine

Autor:innen und Institutionen

  • Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Medical Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Neurology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.

ORCID-Profile: Lana Ganoci, Jozefina Palić, Vladimir Trkulja, Katarina Starčević, Livija Šimičević, Tamara Božina

Förderung

  • Croatian Science Foundation

Zitieren

APA

Ganoci, L., Palić, J., Trkulja, V., Starčević, K., Šimičević, L., Božina, N., Lovrić-Benčić, M., Poljaković, Z., & Božina, T. (2024). Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?. Genes. https://doi.org/10.3390/genes15050607

Vancouver

Ganoci L, Palić J, Trkulja V, Starčević K, Šimičević L, Božina N, et al. Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?. Genes. 2024. doi:10.3390/genes15050607

BibTeX
@article{Ganoci2024,
  author = {Ganoci, Lana and Palić, Jozefina and Trkulja, Vladimir and Starčević, Katarina and Šimičević, Livija and Božina, Nada and Lovrić-Benčić, Martina and Poljaković, Zdravka and Božina, Tamara},
  title = {Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15050607}
}
Kostenlos starten →